Treefrog Therapeutics asked PMC to map the PMDA pathway for its cell therapy platform before committing to a Japanese subsidiary.
Our team translated regulatory milestones into an operating plan: evidence gaps, local partner sequencing, and the documentation rhythm Japanese reviewers expect.
The result was a clear route from feasibility to filing readiness — without losing momentum on the broader Asia strategy.
Regenerative Medicine

